Apolipoprotein E

Apolipoprotein E 詳細

英語名Apolipoprotein E市販薬剤の数0
治験薬の数2ターゲットの別称APOE,Apolipoprotein E,Alzheimer Disease 2 (APOE*E4-Associated, Late Onset),Apolipoprotein E3,LDLCQ5,Apo-E,LPG,AD2,Apolipoproteins E
研究&開発段階Phase 2 Clinical
英語名Apolipoprotein E
ターゲットの別称APOE,Apolipoprotein E,Alzheimer Disease 2 (APOE*E4-Associated, Late Onset),Apolipoprotein E3,LDLCQ5,Apo-E,LPG,AD2,Apolipoproteins E
市販薬剤の数0
治験薬の数2
研究&開発段階Phase 2 Clinical

Apolipoprotein Eバックグランド

APOE is an apolipoprotein, a protein associating with lipid particles, that mainly functions in lipoprotein-mediated lipid transport between organs via the plasma and interstitial fluids. APOE is a core component of plasma lipoproteins and is involved in their production, conversion and clearance. Apoliproteins are amphipathic molecules that interact both with lipids of the lipoprotein particle core and the aqueous environment of the plasma. As such, APOE associates with chylomicrons, chylomicron remnants, very low density lipoproteins (VLDL) and intermediate density lipoproteins (IDL) but shows a preferential binding to high-density lipoproteins (HDL). It also binds a wide range of cellular receptors including the LDL receptor/LDLR, the LDL receptor-related proteins LRP1, LRP2 and LRP8 and the very low-density lipoprotein receptor/VLDLR that mediate the cellular uptake of the APOE-containing lipoprotein particles.

Apolipoprotein E分子の別称

Apolipoprotein E,APOE,Apo-E

治験薬に関する情報

英語名研究コード研究開発ステージ会社適応症臨床試験
CN-105CN-105Phase 2 ClinicalAegiscn LlcCerebral Hemorrhage; Ischemic Stroke; Stroke
詳細
TML-6TML-6Phase 2 ClinicalMerry Life Biomedical Co LtdAlzheimer Disease
詳細
  • 詳細
  • 製品リスト
  • 治験薬に関する情報
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8